Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2019.11.27

C&EN report features Sai Life Sciences

"The surge continues in pharmaceutical services” – C&EN report features Sai Life Sciences

The Chemical & Engineering News, arguably the world's most comprehensive and authoritative news source about chemistry and related fields, featured Sai Life Sciences in its report covering CPhI Worldwide 2019.
Observing the recent trend of contract manufacturing and development firms making transformative investments in their capabilities, C&EN takes the example of Sai Life Sciences, which is investing US $150 Mn in an unprecedented scale up of its facilities. Here’s an extract from the article:

“Another Indian company, Hyderabad-based Sai Life Sciences, is experiencing a growth surge with a near doubling of capacity this year and plans to boost it another 35% by mid-2021, according to CEO Krishna Kanumuri. The majority-family-owned firm also wants to double discovery services capacity in the next 12 months.
Investments are planned at labs in Manchester, England, and Cambridge, Massachusetts, and the firm is building a new research facility at its headquarters that will house 1,500 scientists when complete. Sai will invest $150 million between 2019 and 2023, Kanumuri said.
Behind the surge: “It’s just that our customers have grown,” he said. “We have helped along several companies that have launched molecules commercially over the last 5 years. You start slow, but once you establish yourself, the rate of growth goes up, and that’s where we are at this point.”

Share article

More News

2025.10.31

Sai Life Sciences becomes a signatory to the UN Women’s Empowerment Principles

Sai Life Sciences has joined the global community of signatories to the Women’s Empowerment Principles (WEPs) — an initiative established by UN Women and the UN Global Compact (UNGC). The WEPs serve as a global framework for businesses to advance gender equality and empower women in the workplace, marketplace, and community. By becoming a WEPs […]
Read more

2025.10.27

Sai Life Sciences set to double Process R&D capacity with new facility in Hyderabad

Hyderabad, India, October 27, 2025: Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), today announced the groundbreaking for a new CMC Process R&D Center at its integrated R&D campus in Hyderabad. Scheduled for completion by September 2026, the facility will double the […]
Read more

2025.10.08

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators

Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API […]
Read more

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue. The […]
Read more

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more